We may earn a commission when readers sign up through partner links. Rankings reflect our published methodology, not advertiser fees.
GLP·Agonists Editor's Pick

Conflicts of interest

Conflicts of Interest

Fact-checked by Dr. Adam Kennah, MD on . See our fact-checking policy.

A health publication that pretends not to have conflicts is more dangerous than one that names them. This page names them.

Affiliate relationships

GLP Agonists earns affiliate commissions when readers click a partner link and complete a sign-up. The partners we have active affiliate relationships with as of May 20, 2026:

  • NexLife — affiliate partner; outbound links marked rel="sponsored".

Affiliate relationships do not influence rankings. The same five-pillar scoring methodology is applied to every reviewed program, partner or not. We will not raise a partner's score, lower a non-partner's score, hide a partner's weaknesses, or hide a non-partner's strengths.

Reviewer/provider overlap

Material conflict of interest, disclosed:

Dr. Adam Kennah, MD — one of our clinical reviewers — is also the Medical Director at NexLife, the program we ranked as 2026 Editor's Pick.

What this means in practice

Dr. Kennah's editorial role at GLP Agonists is bounded by a firewall designed to prevent his clinical-review authority from spilling into ranking decisions:

  • What Dr. Kennah does review: Medication names, dosing accuracy, drug-class taxonomy, FDA status, mechanism of action, contraindication lists, drug-drug interactions, common side effects, compounding-standard references.
  • What Dr. Kennah does not review: Provider rankings, comparison conclusions, language describing NexLife relative to competitors, pricing-comparison content, methodology weighting, the five-pillar rubric itself.
  • Independent verification: Clinical claims that specifically concern NexLife (pharmacy sourcing, compounding standards, prescribing protocols) are independently verified by Dr. John Berg, PharmD, who has no relationship with NexLife.
  • Per-page disclosure: Every page that mentions NexLife favorably carries a "Fact-checked by Dr. Adam Kennah, MD" line that lets readers click through to his bio, which discloses his NexLife role.

Other contributor relationships

  • Amanda Chen (Lead Editor) — no equity, advisory, or contracted relationship with any reviewed provider.
  • Dr. John Berg, PharmD (Clinical Reviewer, Pharmacy) — no equity, advisory, or contracted relationship with any reviewed provider, including NexLife.
  • Maria Torres (Contributing Editor, Pricing) — no equity, advisory, or contracted relationship with any reviewed provider.

Ownership & funding

GLP Agonists is an independent editorial publication. It is not owned, operated, or controlled by NexLife, by any other reviewed provider, by any pharmaceutical manufacturer, or by any health-insurance carrier. Revenue is from affiliate commissions and editorial sponsorship of content categories (never of individual rankings).

What we do not accept

  • Direct payment from any reviewed provider in exchange for a ranking position, a "best of" award, or favorable comparison language.
  • Pharmaceutical-manufacturer payments for content concerning their products.
  • Content drafted by a provider's marketing team and presented as editorial.
  • "Provider responses" or "rebuttals" injected into reviews after publication outside the corrections process.

When conflicts change

If a contributor's relationships change — new equity stake, new advisory role, new contracted relationship with a reviewed provider — we update this page and add a corrections-log entry within 14 days. Readers who want to be notified of changes can email glpagonists@gmail.com with the subject line "COI WATCH".

Last reviewed: May 20, 2026.